Search For "drugs controller general of india"
COVID-19: Health ministry decides not to put Itolizumab in national treatm
Updated : 5 years, 7 months ago IST
New Delhi, July 26 (ANI): Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for co
Read More
Domestic pharma giant SII applies to DCGI for phase 2/3 clinical trial of
Updated : 5 years, 7 months ago IST
New Delhi [India], July 25 (ANI): In a development related to the COVID-19 vaccine, the Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) for conducting the Phase 2/3 human clinical trials for a potential coronavirus vaccine.
Read More
DCGI seeks clarification from Glenmark on its anti-viral favipiravir for u
Updated : 5 years, 8 months ago IST
New Delhi [India], July 19 (ANI): The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
Read More
Pharma giant Zydus Cadila initiates clinical study on 1,048 volunteers for
Updated : 5 years, 8 months ago IST
New Delhi [India], July 15 (ANI): Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from D
Read More
Biocon's drug Itolizumab gets DCGI nod for use in moderate to severe Covid
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 11 (ANI): Biopharmaceutical major Biocon Ltd said on Saturday it has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5ml solution for emergency use in India for the treatment of cytokine release syndr
Read More
DCGI instructs pharma giants manufacturing remdesivir to upload details of
Updated : 5 years, 8 months ago IST
New Delhi [India], July 9 (ANI): Witnessing the incidence of black marketing and overcharging of the remdesivir injection above MRP, the Drugs Controller General of India (DCGI) has directed all three pharma giants--Cipla, Hetero, and Mylan to upload the details of anti-viral Remedsivir drug
Read More
Sun Pharma initiates phase two clinical trial on AQCH as potential treatme
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], June 5 (ANI): Sun Pharmaceutical Industries has started phase two clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19.
Read More
Sun Pharma gets DCGI approval for clinical trial with Nafamostat in Covid-
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], May 29 (ANI): Sun Pharmaceutical Industries said on Friday it has received approval from the Drugs Controller General of India (DCGI) to initiate clinical trial with Nafamostat Mesilate in Covid-19 patients.
Read More